Guideline-Directed Medical Therapies for Diabetic Kidney Disease Among Thai People With Type 2 Diabetes
A Real-World Data Based on Theptarin Diabetes Staging
DOI:
https://doi.org/10.15605/jafes.041.01.6239Keywords:
guideline-directed medical therapies (GDMT) prescription rates, diabetic kidney disease, Theptarin Diabetes Staging, ThaiAbstract
Background. The “pillar approach” was recently proposed to holistically address diabetic kidney disease (DKD). Theptarin Diabetes Staging (TDS) is a staging system for type 2 diabetes (T2D) designed to prevent or delay the progression to advanced stages.
Objective. To evaluate the rate of guideline-directed medical therapies (GDMT) among individuals with DKD from 2021 to 2025 according to the TDS system.
Methodology. A retrospective review of medical records of T2D patients with TDS stage 4Ka (moderately increased persistent albuminuria), Stage 4Kb (severely increased persistent albuminuria), and stage 5Ka (eGFR <45 mL/min/1.73 m²) was conducted. The rates of RASi, SGLT2i, GLP-1 RA, and finerenone use, along with achievement of metabolic targets, were evaluated prospectively from 2021 to 2025.
Results. A total of 206 medical records were reviewed (mean age 64.1 ± 10.3 years, A1C 7.3 ± 1.2%, mean eGFR 71.6 ± 24.5 mL/min/1.73 m²). In 2021, the use of RASi was 78.2%, 51.5% for SGLT2i and 13.6% for GLP-1 RA among all patients. Four years later, rates of GDMT improved as follows: RASi 79.7%, SGLT2i 59.3%, GLP-1 RA 19.8% and finerenone 2.8%. However, only 1.1% of all patients in 2025 received all 4 GDMT items. More stable or improved TDS were observed in patients who received GDMT ≥3 classes across all 4 medication classes, compared with those who received GDMT <3 classes (96.2% vs. 78.8%, P-value = 0.036).
Conclusion. The real-world implementation of GDMT among DKD patients remains inadequate, and more efforts are required to improve GDMT adoption. Regular reviews and feedback are warranted to improve attainment of treatment targets and better clinical outcomes.
Downloads
References
Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-84. https://pubmed.ncbi.nlm.nih.gov/8521790 https://doi.org/10.1210/edrv-16-4-460 DOI: https://doi.org/10.1210/edrv-16-4-460
Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5):424-9. https://pubmed.ncbi.nlm.nih.gov/12614096 https://doi.org/10.7326/0003-4819-138-5-200303040-00013 DOI: https://doi.org/10.7326/0003-4819-138-5-200303040-00013
Lam KY, Lo CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol (Oxf). 2001;54(5):633-9. https://pubmed.ncbi.nlm.nih.gov/11380494 https://doi.org/10.1046/j.1365-2265.2001.01266.x DOI: https://doi.org/10.1046/j.1365-2265.2001.01266.x
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1-G34. https://pubmed.ncbi.nlm.nih.gov/27390021 https://doi.org/10.1530/EJE-16-0467 DOI: https://doi.org/10.1530/EJE-16-0467
Fassnacht M, Tsagarakis S, Terzolo M, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2023;189(1):G1-G42. https://doi.org/10.1093/ejendo/lvad066 DOI: https://doi.org/10.1093/ejendo/lvad066
Zeiger MA, Thompson GB, Duh QY, et al. American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. Endocr Pract. 2009;15(5):450-3. https://pubmed.ncbi.nlm.nih.gov/19632968 https://doi.org/10.4158/EP.15.5.450 DOI: https://doi.org/10.4158/EP.15.5.450
Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul). 2017;32(2):200-18. https://pubmed.ncbi.nlm.nih.gov/28685511 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503865 https://doi.org/10.3803/EnM.2017.32.2.200 DOI: https://doi.org/10.3803/EnM.2017.32.2.200
Pelsma ICM, Fassnacht M, Tsagarakis S, et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: Systematic review and meta-analysis. Eur J Endocrinol. 2023;189(4):S88-S101. https://pubmed.ncbi.nlm.nih.gov/37801655 https://doi.org/10.1093/ejendo/lvad134 DOI: https://doi.org/10.1093/ejendo/lvad134
Adamska A, Ulychnyi V, Siewko K, et al. Cardiovascular risk factors in mild adrenal autonomous cortisol secretion in a Caucasian population. Endocr Connect. 2022;11(9):e220074. https://pubmed.ncbi.nlm.nih.gov/35900803 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422244 https://doi.org/10.1530/EC-22-0074 DOI: https://doi.org/10.1530/endoabs.81.EP18
Araujo-Castro M, Reincke M, Lamas C. Epidemiology and management of hypertension and diabetes mellitus in patients with mild autonomous cortisol secretion: A review. Biomedicines. 2023;11(12):3115. https://pubmed.ncbi.nlm.nih.gov/38137336 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740610 https://doi.org/10.3390/biomedicines11123115 DOI: https://doi.org/10.3390/biomedicines11123115
Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery. 2012;152(6):991-7. https://pubmed.ncbi.nlm.nih.gov/23158173 https://doi.org/10.1016/j.surg.2012.08.054 DOI: https://doi.org/10.1016/j.surg.2012.08.054
Koh JM, Song K, Kwak MK, et al. Adrenalectomy improves body weight, glucose, and blood pressure control in patients with mild autonomous cortisol secretion: Results of a randomized controlled trial by the Co-work of Adrenal Research (COAR) study. Ann Surg. 2024;279(6):945-52. https://pubmed.ncbi.nlm.nih.gov/38126763 https://doi.org/10.1097/SLA.0000000000006183 DOI: https://doi.org/10.1097/SLA.0000000000006183
Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: A new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998-1003. https://pubmed.ncbi.nlm.nih.gov/11889151 https://doi.org/10.1210/jcem.87.3.8277 DOI: https://doi.org/10.1210/jc.87.3.998
Favero V, Cremaschi A, Parazzoli C, et al. Pathophysiology of mild hypercortisolism: From the bench to the bedside. Int J Mol Sci. 2022;23(2):673. https://pubmed.ncbi.nlm.nih.gov/35054858 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775422 https://doi.org/10.3390/ijms23020673 DOI: https://doi.org/10.3390/ijms23020673
Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-70. https://pubmed.ncbi.nlm.nih.gov/21471169 https://doi.org/10.1530/EJE-10-1147 DOI: https://doi.org/10.1530/EJE-10-1147
Androulakis II, Kaltsas GA, Kollias GE, et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab. 2014;99(8):2754-62. https://doi.org/10.1210/jc.2013-4064 DOI: https://doi.org/10.1210/jc.2013-4064
Park SH, Kim MJ, Kim JH, et al. Differentiation of adrenal adenoma and nonadenoma in unenhanced CT: New optimal threshold value and the usefulness of size criteria for differentiation. Korean J Radiol. 2007;8(4):328-35. https://pubmed.ncbi.nlm.nih.gov/17673844 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627166 https://doi.org/10.3348/kjr.2007.8.4.328 DOI: https://doi.org/10.3348/kjr.2007.8.4.328
Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871-7. https://pubmed.ncbi.nlm.nih.gov/15572420 https://doi.org/10.1210/jc.2004-1627 DOI: https://doi.org/10.1210/jc.2004-1627
Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab. 2021;106(11):3331-53. https://pubmed.ncbi.nlm.nih.gov/34260734 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530736 https://doi.org/10.1210/clinem/dgab512 DOI: https://doi.org/10.1210/clinem/dgab512
Stavropoulos K, Imprialos KP, Katsiki N, et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone? J Clin Hypertens (Greenwich). 2018;20(5):942-8. https://pubmed.ncbi.nlm.nih.gov/29722113 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031295 https://doi.org/10.1111/jch.13291 DOI: https://doi.org/10.1111/jch.13291
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. https://pubmed.ncbi.nlm.nih.gov/26934393 https://doi.org/10.1210/jc.2015-4061 DOI: https://doi.org/10.1210/jc.2015-4061
Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: A systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107-16. https://pubmed.ncbi.nlm.nih.gov/31234202 https://doi.org/10.7326/M18-3630 DOI: https://doi.org/10.7326/M18-3630
Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. J Clin Endocrinol Metab. 2014;99(3):827-34. https://pubmed.ncbi.nlm.nih.gov/24423350 https://doi.org/10.1210/jc.2013-3527 DOI: https://doi.org/10.1210/jc.2013-3527
Pasternak JD, Seib CD, Seiser N, et al. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg. 2015;150(10):974-8. https://pubmed.ncbi.nlm.nih.gov/26200882 https://doi.org/10.1001/jamasurg.2015.1683 DOI: https://doi.org/10.1001/jamasurg.2015.1683
Vassiliadi DA, Ntali G, Stratigou T, et al. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine. 2011;40(3):437-44. https://pubmed.ncbi.nlm.nih.gov/21598069 https://doi.org/10.1007/s12020-011-9490-1 DOI: https://doi.org/10.1007/s12020-011-9490-1
Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: A 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405. https://pubmed.ncbi.nlm.nih.gov/24795253 https://doi.org/10.1016/S2213-8587(13)70211-0 DOI: https://doi.org/10.1016/S2213-8587(13)70211-0
Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736-45. https://pubmed.ncbi.nlm.nih.gov/20375210 https://doi.org/10.1210/jc.2009-2387 DOI: https://doi.org/10.1210/jc.2009-2387
Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-85. https://pubmed.ncbi.nlm.nih.gov/14514341 https://doi.org/10.1530/eje.0.1490273 DOI: https://doi.org/10.1530/eje.0.1490273
Giovanelli L, Aresta C, Favero V, et al. Hidden hypercortisolism: A too frequently neglected clinical condition. J Endocrinol Invest. 2021;44(8):1581-96. https://pubmed.ncbi.nlm.nih.gov/33394454 https://doi.org/10.1007/s40618-020-01484-2 DOI: https://doi.org/10.1007/s40618-020-01484-2
Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: Consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519-48. https://pubmed.ncbi.nlm.nih.gov/29905835 https://doi.org/10.1210/er.2018-00097 DOI: https://doi.org/10.1210/er.2018-00097
Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res. 2011;26(8):1816-21. https://pubmed.ncbi.nlm.nih.gov/21472775 https://doi.org/10.1002/jbmr.398 DOI: https://doi.org/10.1002/jbmr.398
Hadjidakis D, Tsagarakis S, Roboti C, et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol (Oxf). 2003;58(1):72-7. https://pubmed.ncbi.nlm.nih.gov/12519415 https://doi.org/10.1046/j.1365-2265.2003.01676.x DOI: https://doi.org/10.1046/j.1365-2265.2003.01676.x
Pal R, Banerjee M, Prasad TN, et al. Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion/subclinical hypercortisolism: A systematic review, meta-analysis and meta-regression. J Bone Miner Res. 2024;39(7):885-97. https://pubmed.ncbi.nlm.nih.gov/38703381 https://doi.org/10.1093/jbmr/zjae067 DOI: https://doi.org/10.1093/jbmr/zjae067
Tabarin A, Espiard S, Deutschbein T, et al. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): A multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):580-90. https://pubmed.ncbi.nlm.nih.gov/40373786 https://doi.org/10.1016/S2213-8587(25)00062-2 DOI: https://doi.org/10.1016/S2213-8587(25)00062-2
Ren X, Nan M, Zhang X. Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: A meta-analysis. Front Endocrinol (Lausanne). 2024;15:1399311. https://pubmed.ncbi.nlm.nih.gov/39086899 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288901 https://doi.org/10.3389/fendo.2024.1399311 DOI: https://doi.org/10.3389/fendo.2024.1399311
Cho YY, Suh S, Joung JY, et al. Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med. 2013;28(5):557-64. https://pubmed.ncbi.nlm.nih.gov/24009451 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759761 https://doi.org/10.3904/kjim.2013.28.5.557 DOI: https://doi.org/10.3904/kjim.2013.28.5.557
Liu M, Zhao W, Zhang W, et al. Comparable cognitive impairment was detected in MACS and CS and alleviated after remission of hypercortisolism in MACS. Front Endocrinol (Lausanne). 2024;15:1373101. https://pubmed.ncbi.nlm.nih.gov/39145316 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322108 https://doi.org/10.3389/fendo.2024.1373101 DOI: https://doi.org/10.3389/fendo.2024.1373101
Luk Y, Tsang VHM, Lo C, Lee R, Cheung YT, Wong KK, et al. Prevalence of mild autonomous cortisol secretion in adrenal incidentalomas and the significance of subcentimeter adrenal nodules: A single-center cohort study. Endocr Pract. 2025;31(12):1576-84. https://doi.org/10.1016/j.eprac.2025.07.018 DOI: https://doi.org/10.1016/j.eprac.2025.07.018
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Peachaphol Chongvoranond , Waralee Chatchomchuan, Ekgaluck Wanothayaroj , Siriwan Butadej , Soontaree Nakasatien, Thep Himathongkam, Yotsapon Thewjitcharoen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
